Rheumatoid Arthritis and Interstitial Lung Disease

From a western clinical standpoint, interstitial lung disease represents a significant extra‑articular manifestation of rheumatoid arthritis. Population‑based and cohort studies estimate 5–10% of people with RA develop clinically apparent ILD, while HRCT reveals a larger pool of subclinical disease. RA‑ILD often emerges within the first decade of RA, though it can precede arthritis. Risk focuses on older adults—disproportionately men—who smoke or have inhalational exposures, carry high RF or anti‑CCP titers, or possess genetic susceptibility such as the MUC5B promoter variant. These converging risks reflect how autoimmunity and fibrotic repair programs become entrenched in the lung. Pathobiologically, the lung is both a target and, potentially, a site where RA autoimmunity is initiated. Cigarette smoke and other irritants promote citrullination and mucosal immune activation, leading to local production of RA‑related autoantibodies. Persistent systemic inflammation and cytokines (TNF‑α, IL‑6, TGF‑β) sustain epithelial injury and fibroblast activation, culminating in fibrosing phenotypes—most commonly usual interstitial pneumonia (UIP), which carries a poorer prognosis than nonspecific interstitial pneumonia (NSIP). Diagnosis hinges on attentive screening and early referral. Symptoms such as exertional dyspnea, dry cough, or bibasilar crackles prompt PFTs with DLCO and HRCT for pattern recognition. For high‑risk RA patients, baseline and periodic PFTs are reasonable, with HRCT guided by symptoms or test changes. Collaboration between rheumatology and pulmonology is essential for phenotype‑driven care. Treatment balances inflammation control and antifibrotic strategies. Immunomodulators with emerging pulmonary safety/benefit signals include rituximab and abatacept; mycophenolate and cyclophosphamide are frequently used for inflammatory ILD. Short courses of glucocorticoids may help acute exacerbations. Antifibrotic therapy (nintedanib) slows FVC decline in progressive fibrosing ILD, including RA‑ILD, regardless of ongoing immunosuppression. Medication selection weighs pulmonary effects: methotrexate rarely causes acute pneumonitis and likely does not increase chronic ILD risk; leflunomide and, less consistently, anti‑TNF agents have been linked to ILD worsening in susceptible patients. Nonpharmacologic care—pulmonary rehabilitation, smoking cessation, vaccination, oxygen when indicated, and nutrition/physical therapy—supports function and safety. Because ILD markedly influences RA survival and quality of life, proactive surveillance and integrated care can meaningfully alter trajectories.

Traditional and integrative frameworks view the RA–lung connection as a systemic disturbance manifesting in two organ systems. In Traditional Chinese Medicine (TCM), RA aligns with Bi syndrome—pathogenic Wind, Cold, and Damp obstructing the channels—while chronic cough and breathlessness reflect Lung Qi or Yin deficiency with phlegm accumulation. Over time, unresolved obstruction becomes ‘stasis’ that mirrors fibrosis. Ayurveda similarly situates RA and chronic respiratory complaints in imbalances of Vata and Kapha with Ama (toxic residue) and impaired Agni (digestive/metabolic fire), which fuel widespread inflammation and congestion. Treatment principles emphasize restoring free flow, reducing pathogenic accumulation, and strengthening underlying deficiencies. Acupuncture and moxibustion are used for pain, stiffness, and stress regulation; small clinical trials suggest modest improvements in RA symptoms and functional scores. For respiratory support, gentle qi gong, tai chi, or yoga with breathwork (pranayama) can complement pulmonary rehabilitation by enhancing body awareness, easing anxiety, and improving exercise tolerance within oxygen limitations. Diets that are warm, easily digestible, and anti‑inflammatory align with both Ayurveda and TCM aims and may support energy balance during chronic illness. Herbal approaches are nuanced. Boswellia (Ayurveda) has anti‑inflammatory properties that may ease joint symptoms. TCM formulas to ‘transform phlegm’ and nourish Lung/Kidney Yin are traditionally used for chronic cough and fatigue. However, herb–drug interactions and immunologic effects are critical considerations for people on immunosuppressants; some agents (e.g., Tripterygium wilfordii) have documented efficacy for RA but carry significant toxicity and should only be contemplated under expert supervision within a coordinated care plan. Integrative clinicians typically prioritize low‑risk adjuncts—acupuncture, mind–body practices, sleep optimization, and nutrition—while collaborating closely with rheumatology and pulmonology teams. Framed this way, eastern and western models converge on reducing inflammation, supporting resilience, and preventing exacerbations, while honoring the need for individualized, safety‑first care.